We believe that Phytomedicine will effectively treat previously unmet medical needs and improve the lives of patients, impacting public health across the world.
MGC embraces this by creating Phytocannabinoid-based medicine products and providing them in targeted markets. These products are registered for sale and leverage the Company’s own proprietary medical cannabis formula through clinical trials in Europe, Israel and Australia. In addition, tertiary and supplementary revenue streams solidify our presence in the market.
This enables future medical product sales across the European Union, Australia, and other geographies, following the requisite legal and regulatory approvals.
To be a global leader in Phytocannabinoid-based medicines within the biopharmaceutical industry.
MGC Pharma’s goal is to facilitate the transformation of Phytocannabinoids into true medicinal product pipelines, and to provide breakthrough solutions for prevalent global health issues to improve the quality of patients’ lives and contribute to improved public health. MGC Pharma aims to build a responsible and profitable industry.
To Build an Innovative, Vertically Integrated bio-pharma company providing Standardised, Affordable Phytocannabinoid Derived Medicines of the Highest Regulatory Compliance for Targeted global markets and patients